Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor

Molecular Immunology

Volumn 46, Issue 1, 2008, Pages 192-201

  Yi, Hwa Jung ^a   Chae, Chang Suk ^a   So, Jae Seon ^a   Tzartos, Socrates J ^b,c   Souroujon, Miriam C ^d   Fuchs, Sara ^e   Im, Sin Hyeog ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d OPEN UNIVERSITY OF ISRAEL   (Israel)

^e WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Autoimmune disease; Autoimmunity; B cell epitope; EAMG; Myasthenia gravis; Oral tolerance; Tolerogen

Indexed keywords

AUTOANTIGEN; B CELL EPITOPE FREE RECOMBINANT ACETYLCHOLINE RECEPTOR; CD4 ANTIGEN; CYTOKINE; EPITOPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 10; OVALBUMIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRX HALPHA1 210; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; CYTOKINES; DOWN-REGULATION; EPITOPES, B-LYMPHOCYTE; FEMALE; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; RECOMBINANT PROTEINS; SEQUENCE DELETION; T-LYMPHOCYTES; TH1 CELLS;

RATTUS;

EID: 52949127957     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.08.264     Document Type: Article

References (56)

1. Aharonov A., Tarrab-Hazdai R., Silman I., and Fuchs S. Immunochemical studies on acetylcholine receptor from Torpedo californica. Immunochemistry 14 (1977) 129-137
2. Balasa B., Deng C., Lee J., Bradley L.M., Dalton D.K., Christadoss P., and Sarvetnick N. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186 (1997) 385-391
3. Barchan D., Asher O., Tzartos S.J., Fuchs S., and Souroujon M.C. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Eur. J. Immunol. 28 (1998) 616-624
4. Barnett M.L., Kremer J.M., St Clair E.W., Clegg D.O., Furst D., Weisman M., Fletcher M.J., Chasan-Taber S., Finger E., Morales A., Le C.H., and Trentham D.E. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 41 (1998) 290-297
5. Beeson D., Morris A., Vincent A., and Newsom-Davis J. The human muscle nicotinic acetylcholine receptor alpha-subunit exist as two isoforms: a novel exon. EMBO J. 9 (1990) 2101-2106
6. Bellmann K., Kolb H., Rastegar S., Jee P., and Scott F.W. Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: a protocol effective in NOD mice may exacerbate disease in BB rats. Diabetologia 41 (1998) 844-847
7. Bergerot I., Fabien N., Mayer A., and Thivolet C. Active suppression of diabetes after oral administration of insulin is determined by antigen dosage. Ann. N. Y. Acad. Sci. 778 (1996) 362-367
8. Blanas E., Carbone F.R., Allison J., Miller J.F.A.P., and Heath W.R. Induction of autoimmune diabetes by oral administration of autoantigen. Science 274 (1996) 1707-11709
9. Conti-Fine B.M., Milani M., and Kaminski H.J. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116 (2006) 2843-2854
10. Deng C., Goluszko E., Tuzun E., Yang H., and Christadoss P. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 169 (2002) 1077-1083
11. Drachman D.B. Immunotherapy in neuromuscular disorders: current and future strategies. Muscle Nerve 19 (1996) 1239-1251
12. Faria A.M., and Weiner H.L. Oral tolerance. Immunol. Rev. 206 (2005) 232-259
13. Finck B.K., Linsley P.S., and Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 265 (1994) 1225-1227
14. Friedman A., and Weiner H.L. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 6688-6692
15. Girvin A.M., Dal Canto M.C., Rhee L., Salomon B., Sharpe A., Bluestone J.A., and Miller S.D. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J. Immunol. 164 (2000) 136-143
16. Gregerson D.S., Obritsch W.F., and Donoso L.A. Oral tolerance in experimental autoimmune uveoretinitis. Distinct mechanisms of resistance are induced by low dose vs high dose feeding protocols. J. Immunol. 151 (1993) 5751-5761
17. Im S.H., Barchan D., Fuchs S., and Souroujon M.C. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J. Clin. Invest. 104 (1999) 1723-1730
18. Im S.H., Barchan D., Souroujon M.C., and Fuchs S. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis. J. Immunol. 165 (2000) 3599-3605
19. Karachunski P.I., Ostlie N.S., Monfardini C., and Conti-Fine B.M. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J. Immunol. 164 (2000) 5236-5244
20. Karandikar N.J., Vanderlugt C.L., Walunas T.L., Miller S.D., and Bluestone J.A. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184 (1996) 783-788
21. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu. Rev. Immunol. 8 (1990) 773-793
22. Lennon V.A., and Lambert E.H. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature 285 (1980) 238-240
23. Lennon V.A., Lindstrom J.M., and Seybold M.E. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 141 (1975) 1365-1375
24. Lennon V.A., McCormick D.J., Lambert E.H., Griesmann G.E., and Atassi M.Z. Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 8805-8809
25. Lenschow D.J., Walunas T.L., and Bluestone J.A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14 (1996) 233-258
26. Li J., Tuzun E., Wu X.R., Qi H.B., Allman W., Saini S.S., and Christadoss P. Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis. J. Neuroimmunol. 194 (2008) 44-53
27. Lundin B.S., Karlsson M.R., Svensson L.A., Hanson L.A., Dahlgren U.I., and Telemo E. Active suppression in orally tolerized rats coincides with in situ transforming growth factor-beta (TGF-beta) expression in the draining lymph nodes. Clin. Exp. Immunol. 116 (1999) 181-187
28. Maiti P.K., Feferman T., Im S.H., Souroujon M.C., and Fuchs S. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J. Neuroimmunol. 152 (2004) 112-120
29. Mamula M.J., Fatenejad S., and Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J. Immunol. 152 (1994) 1453-1461
30. Matusevicius D., Navikas V., Palasik W., Pirskanen R., Fredrikson S., and Link H. Tumor necrosis factor-alpha, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. J. Neuroimmunol. 71 (1996) 191-198
31. Metzler B., and Wraith D.C. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int. Immunol. 5 (1993) 1159-1165
32. Mizumachi K., Tsuji N.M., and Kurisaki J.-I. Suppression of immune responses to beta-lactoglobulin in mice by the oral administration of peptides representing dominant T cell epitopes. J. Sci. Food Agric. 88 (2008) 542-549
33. Mochly-Rosen D., and Fuchs S. Monoclonal anti-acetylcholine-receptor antibodies directed against the cholinergic binding site. Biochemistry 20 (1981) 5920-5924
34. Moiola L., Galbiati F., Martino G., Amadio S., Brambilla E., Comi G., Vincent A., Grimaldi L.M., and Adorini L. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur. J. Immunol. 28 (1998) 2487-2497
35. Nagler-Anderson C., Bober L.A., Robinson M.E., Siskind G.W., and Thorbecke G.J. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 7443-7446
36. Newland C.F., Beeson D., Vincent A., and Newsom-Davis J. Functional and non-functional isoforms of the human muscle acetylcholine receptor. J. Physiol. 489 (1995) 767-778
37. Nussenblatt R.B., Whitcup S.M., de Smet M.D., Caspi R.R., Kozhich A.T., Weiner H.L., Vistica B., and Gery I. Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann. N. Y. Acad. Sci. 778 (1996) 325-337
38. Pierce S.K., Morris J.F., Grusby M.J., Kaumaya P., van Buskirk A., Srinivasan M., Crump B., and Smolenski L.A. Antigen-presenting function of B lymphocytes. Immunol. Rev. 106 (1988) 149-180
39. Schatz D.A., Rogers D.G., and Brouhard B.H. Prevention of insulin-dependent diabetes mellitus: an overview of three trials. Cleve. Clin. J. Med. 63 (1996) 270-274
40. Shi F.D., He B., Li H., Matusevicius D., Link H., and Ljunggren H.G. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur. J. Immunol. 28 (1998) 3587-3593
41. Souroujon M.C., Mochly-Rosen D., Gordon A.S., and Fuchs S. Interaction of monoclonal antibodies to Torpedo acetylcholine receptor with the receptor of skeletal muscle. Muscle Nerve 6 (1983) 303-311
42. Sun J.B., Raghavan S., Sjoling A., Lundin S., and Holmgren J. Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+ and Foxp3-CD25-CD4+ regulatory T cells. J. Immunol. 177 (2006) 7634-7644
43. Teleshova N., Matusevicius D., Kivisakk P., Mustafa M., Pirskanen R., and Link H. Altered expression of costimulatory molecules in myasthenia gravis. Muscle Nerve 23 (2000) 946-953
44. Thompson H.S., and Staines N.A. Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin. Exp. Immunol. 64 (1986) 581-586
45. Tian J., Olcott A., Hanssen L., Zekzer D., and Kaufman D.L. Antigen-based immunotherapy for autoimmune disease: from animal models to humans?. Immunol. Today 20 (1999) 190-195
46. Tian J., Zekzer D., Lu Y., Dang H., and Kaufman D.L. B cells are crucial for determinant spreading of T cell autoimmunity among beta cell antigens in diabetes-prone nonobese diabetic mice. J. Immunol. 176 (2006) 2654-2661
47. Trentham D.E., Dynesius-Trentham R.A., Orav E.J., Combitchi D., Lorenzo C., Sewell K.L., Hafler D.A., and Weiner H.L. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261 (1993) 1727-1730
48. Tzartos S.J., Kokla A., Walgrave S.L., and Conti-Tronconi B.M. Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the alpha subunit. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 2899-2903
49. Tzartos S.J., and Lindstrom J.M. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc. Natl. Acad. Sci. U.S.A. 77 (1980) 755-759
50. Weiner H.L., Mackin G.A., Matsui M., Orav E.J., Khoury S.J., Dawson D.M., and Hafler D.A. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259 (1993) 1321-1324
51. Yan J., Harvey B.P., Gee R.J., Shlomchik M.J., and Mamula M.J. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J. Immunol. 177 (2006) 4481-4487
52. Yoshikawa H., Lambert E.H., Walser-Kuntz D.R., Yasukawa Y., McCormick D.J., and Lennon V.A. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis. J. Immunol. 159 (1997) 1570-1577
53. Zhang G.X., Xiao B.G., Bai X.F., Orn A., van der Meide P.H., and Link H. IFN-gamma is required to induce experimental autoimmune myasthenia gravis. Ann. N. Y. Acad. Sci. 841 (1998) 576-579
54. Zhang Y., and Tzartos S. B-T lymphocyte interactions in experimental autoimmune myasthenia gravis: autoantibody mediated up-regulation of the response of acetylcholine receptor-specific T lymphocytes. Immunology 77 (1992) 571-576
55. Zhang Y.P., Tzartos S.J., and Wekerle H. B-T lymphocyte interactions in experimental autoimmune myasthenia gravis: antigen presentation by rat/mouse hybridoma lines secreting monoclonal antibodies against the nicotinic acetylcholine receptor. Eur. J. Immunol. 18 (1988) 211-218
56. Zhang X., Izikson L., Liu L., and Weiner H.L. Activation of CD25+CD4+ regulatory T cells by oral antigen administration. J. Immunol. 167 (2001) 4245-4253